%0 Figure %A Shitara, Kohei %A Satoh, Taroh %A Iwasa, Satoru %A Yamaguchi, Kensei %A Muro, Kei %A Komatsu, Yoshito %A Nishina, Tomohiro %A Esaki, Taito %A Hasegawa, Jun %A Kakurai, Yasuyuki %A Kamiyama, Emi %A Nakata, Tomoko %A Nakamura, Kota %A Sakaki, Hayato %A Hyodo, Ichinosuke %D 2019 %T Additional file 7: of Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors %U https://springernature.figshare.com/articles/figure/Additional_file_7_of_Safety_tolerability_pharmacokinetics_and_pharmacodynamics_of_the_afucosylated_humanized_anti-EPHA2_antibody_DS-8895a_a_first-in-human_phase_I_dose_escalation_and_dose_expansion_study_in_patients_with_advanced_solid_tumo/9631238 %R 10.6084/m9.figshare.9631238.v1 %2 https://springernature.figshare.com/ndownloader/files/17280809 %K Erythropoietin-producing hepatocellular receptor A2 %K Gastric cancer %K Esophageal cancer %K Advanced solid tumors %K DS-8895a %K Antibody-dependent cellular cytotoxicity %K Phase I study %X Disposition of patients. †One patient was excluded from the efficacy analysis set because no efficacy data were available. ‡One patient was excluded from the PK analysis set because no PK data were available. Abbreviation: PK, pharmacokinetics. (TIF 224 kb) %I figshare